Skip to main content
Premium Trial:

Request an Annual Quote

BD Segment GeneOhm Settles MRSA IP Tussle with BioMérieux

NEW YORK (GenomeWeb News) - GeneOhm Sciences Canada, a subsidiary of Becton Dickinson, has agreed to settle a dispute with BioMérieux related to “several license agreements” between the companies, BioMérieux said today. The company did not disclose financial details of the settlement.
The dispute began in April, when BioMérieux filed for arbitration proceedings against GeneOhm in the ICC International Court of Arbitration in Paris related to intellectual property rights for diagnostics for methycillin-resistant Staphylococcus aureus.
BioMérieux CEO Stéphane Bancel said the settlement “confirms the relevance” of its IP rights in this particular diagnostics field. Bancel added that the company “intends to play a major role in protecting patients from healthcare-associated infections.”
BioMérieux in April filed another dispute that claimed that BD breached a license agreement related to BD’s Bactec blood culture products. BioMérieux claimed BD was selling those products “in non-licensed fields.”
BD said at the time it saw “no material breach of the agreement, and said it planned to defend its right to sell the Bactec line in those disputed areas.
BioMérieux did not comment today on the status of the Bactec dispute.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.